Impact of Collaborative Care for Pregnant Women With Opioid Use Disorder in Low-Resource Obstetric Settings
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Elizabeth Krans, MD · PRINCIPAL_INVESTIGATOR · University of Pittsburgh
- Marian Jarlenski, PhD · PRINCIPAL_INVESTIGATOR · University of Pittsburgh
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Patient Initiation of Medication for Opioid Use Disorder (MOUD)During pregnancy (up to 40 weeks), up to 1 year post delivery
Patient Initiation of Medication for Opioid Use Disorder (MOUD) as measured by total buprenorphine or methadone initiation in Electronic Health Record (EHR) and Medicaid claims data
- Patient Duration of MOUDDuring pregnancy (up to 40 weeks), up to 1 year post delivery
Patient Duration of MOUD as measured by proportion of days' covered incorporating buprenorphine or methadone treatment in EHR and claims data
- Patient OverdoseDuring pregnancy (up to 40 weeks), up to 1 year post delivery
Patient Overdose as measured by total count of nonfatal or fatal overdose events in EHR and claims data
- Patient child foster care placementDelivery through 1 year postpartum
Patient child foster care placement as measured by total child placements in foster care system according to child protective service data linked with Medicaid data
- Patient utilization of well-child servicesDelivery through 1 year postpartum
Patient utilization of well-child services as measured by total well-child visits in EHR and claims data